Medistem is developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The Company has filed an Investigational New Drug (IND) application with the FDA for use of its universal donor endometrial regenerative cells (ERC) for treatment of critical limb ischemia, an advanced form of peripheral artery disease. Medistem also sells the ERC cells for research at the General Biotechnology LLC website.
In this particular study, a 29 year old patient who had suffered spinal injuries from a plane crash on May 13, 2008 had lost the ability to walk, sporatic pain and lost sexual function. After injections of the combination universal donor stem cells (not matched to a specific person) in November of 2008 and then again in January and July of 2009, a gradual improvement was observed. To date, the patient has regained sexual function, pain has significantly decreased and the ability to walk has been regained.